BioCentury | Dec 4, 2020
Finance

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

...of cancer company Quanticel Pharmaceuticals Inc., which Celgene Corp....
BioCentury | Dec 1, 2020
Product Development

With new Phase III results in rare anemia, Agios moves toward first non-oncology submission

...in revenue during the first nine months of 2020; the company receives royalties from BMS’s Celgene Corp....
BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

...Shanghai company with Celgene roots raises $360M Hong...
...founder, Chairman and CEO Jay Mei, a Celgene Corp....
...eventually landed the landmark cross-border deal between Celgene...
BioCentury | Nov 17, 2020
Deals

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

...right worth up to $6.8 billion that was issued in BMS’s $74 billion acquisition of Celgene Corp....
BioCentury | Nov 7, 2020
Politics, Policy & Law

CIRM refuels with $5.5B and a chance to improve its track record

...was Inrebic fedratinib, a small molecule myelofibrosis drug from Celgene Corp....
BioCentury | Nov 6, 2020
Management Tracks

BeiGene’s pathfinding CFO Liang to retire

...on the Hong Kong stock exchange that brought in $900 million and transformative deals with Celgene Corp....
BioCentury | Nov 6, 2020
Regulation

Pressure builds for Celgene payout as BMS faces possible liso-cel delay

...payout tied to the pharma’s acquisition of Celgene.Samit...
...CVR issued in BMS’s $74 billion acquisition of Celgene Corp....
...gained ide-cel through the Celgene deal, via Celgene’s...
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...and Faheem Hasnain as executive advisors. Golumbeski was most recently EVP of business development at Celgene Corp....
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

...forged other deals, including a partnership with Celgene Corp....
...peripheral blood mononuclear cells.”After its acquisition of Celgene...
BioCentury | Oct 13, 2020
Product Development

Gossamer takes a nosedive on Phase II results, but sees path forward in asthma

...$1 billion in public and private financings since 2017.Gujrathi was CMO at Receptos Inc., which Celgene Corp....
Items per page:
1 - 10 of 3368
BioCentury | Dec 4, 2020
Finance

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

...of cancer company Quanticel Pharmaceuticals Inc., which Celgene Corp....
BioCentury | Dec 1, 2020
Product Development

With new Phase III results in rare anemia, Agios moves toward first non-oncology submission

...in revenue during the first nine months of 2020; the company receives royalties from BMS’s Celgene Corp....
BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

...Shanghai company with Celgene roots raises $360M Hong...
...founder, Chairman and CEO Jay Mei, a Celgene Corp....
...eventually landed the landmark cross-border deal between Celgene...
BioCentury | Nov 17, 2020
Deals

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

...right worth up to $6.8 billion that was issued in BMS’s $74 billion acquisition of Celgene Corp....
BioCentury | Nov 7, 2020
Politics, Policy & Law

CIRM refuels with $5.5B and a chance to improve its track record

...was Inrebic fedratinib, a small molecule myelofibrosis drug from Celgene Corp....
BioCentury | Nov 6, 2020
Management Tracks

BeiGene’s pathfinding CFO Liang to retire

...on the Hong Kong stock exchange that brought in $900 million and transformative deals with Celgene Corp....
BioCentury | Nov 6, 2020
Regulation

Pressure builds for Celgene payout as BMS faces possible liso-cel delay

...payout tied to the pharma’s acquisition of Celgene.Samit...
...CVR issued in BMS’s $74 billion acquisition of Celgene Corp....
...gained ide-cel through the Celgene deal, via Celgene’s...
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...and Faheem Hasnain as executive advisors. Golumbeski was most recently EVP of business development at Celgene Corp....
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

...forged other deals, including a partnership with Celgene Corp....
...peripheral blood mononuclear cells.”After its acquisition of Celgene...
BioCentury | Oct 13, 2020
Product Development

Gossamer takes a nosedive on Phase II results, but sees path forward in asthma

...$1 billion in public and private financings since 2017.Gujrathi was CMO at Receptos Inc., which Celgene Corp....
Items per page:
1 - 10 of 3368